Skip to content
Screener

Exelixis EXEL COMETRIQ — Total revenues

Other product segments

Gross product revenues
$812.78M+9.1%
Discounts and allowances
-$239.76M-6.4%
License revenues
$59.81M+21.3%
Collaboration
$55.67M+15.4%
Collaboration services revenues
-$4.53M-80.8%

Similar metrics at other companies

Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
ALN
ALNYRoyalty revenue — Total revenues
$71.67M+79.3%
Hyatt Hotels logo
HContra revenue — Total revenues
-$17M-13.3%
FTAI Aviation Ltd. logo
FTAIMaintenance revenue — Total revenues
$30.6M-38.3%
FTAI Aviation Ltd. logo
FTAIOther revenue — Total revenues
$6.21M+19,923%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
CABOMETYX$570,648$517,890$1,123,421$1,028,762
COMETRIQ2,3772,1244,5814,535
Net product revenues$573,025$520,014$1,128,002$1,033,297

Item 1. Financial Statements.

FAQ

What is Exelixis's COMETRIQ — total revenues?
Exelixis (EXEL) reported COMETRIQ — total revenues of $2.38M in Q2 2026.
How has Exelixis's COMETRIQ — total revenues changed year-over-year?
Exelixis's COMETRIQ — total revenues increased by 11.9% year-over-year, from $2.12M to $2.38M.
What is the long-term trend for Exelixis's COMETRIQ — total revenues?
Over 4 years (2021 to 2025), Exelixis's COMETRIQ — total revenues has grown at a -20.1% compound annual growth rate (CAGR), from $23.21M to $9.44M.
What does COMETRIQ — total revenues mean?
This metric represents the total gross revenue generated from the sale of a specific oncology therapeutic product. It captures the financial performance of a mature drug asset within the company's portfolio, reflecting market adoption and competitive positioning in its indicated treatment areas. This figure is critical for assessing the lifecycle stage and revenue contribution of individual pharmaceutical assets.

Ask your AI about Exelixis's cometriq — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude